Institute of Experimental Endocrinology and Oncology "G. Salvatore" (IEOS), National Research Council (CNR), 80131 Naples, Italy.
S.S.D. Sperimentazione Animale, Istituto Nazionale Tumori⁻IRCCS⁻Fondazione G. Pascale, 80131 Naples, Italy.
Genes (Basel). 2019 Feb 9;10(2):127. doi: 10.3390/genes10020127.
PATZ1 is a transcriptional factor downregulated in thyroid cancer whose re-expression in thyroid cancer cells leads to a partial reversion of the malignant phenotype, including the capacity to proliferate, migrate, and undergo epithelial-to-mesenchymal transition. We have recently shown that is specifically downregulated downstream of the Ras oncogenic signaling through miR-29b, and that restoration of in Ha-Ras transformed FRTL5 rat thyroid cells is able to inhibit their capacities to proliferate and migrate in vitro. Here, we analyzed the impact of expression on the in vivo tumorigenesis of these cells. Surprisingly, FRTL5-Ras-PATZ1 cells showed enhanced tumor initiation when engrafted in nude mice, even if their tumor growth rate was reduced compared to that of FRTL5-Ras control cells. To further investigate the cause of the enhanced tumor engraftment of FRTL5-Ras-PATZ1 cells, we analyzed the stem-like potential of these cells through their capacity to grow as thyrospheres. The results showed that restoration of expression in these cells increases stem cell markers' expression and self-renewal ability of the thyrospheres while limiting their growth capacity. Therefore, we suggest that PATZ1 may play a role in enhancing the stem cell potential of thyroid cancer cells, but, at the same time, it impairs the proliferation of non-stem cells.
PATZ1 是一种在甲状腺癌中下调的转录因子,其在甲状腺癌细胞中的重新表达导致恶性表型的部分逆转,包括增殖、迁移和上皮-间充质转化的能力。我们最近表明, 通过 miR-29b, 特异性地下调 Ras 致癌信号下游的 ,并且在 Ha-Ras 转化的 FRTL5 大鼠甲状腺细胞中恢复 能够抑制它们在体外的增殖和迁移能力。在这里,我们分析了 表达对这些细胞体内致瘤性的影响。令人惊讶的是,即使与 FRTL5-Ras 对照细胞相比,FRTL5-Ras-PATZ1 细胞在裸鼠中植入时显示出增强的肿瘤起始能力,但它们的肿瘤生长速度却降低了。为了进一步研究 FRTL5-Ras-PATZ1 细胞增强的肿瘤植入的原因,我们通过它们作为甲状腺球体生长的能力分析了这些细胞的类干细胞潜力。结果表明,在这些细胞中恢复 表达会增加干细胞标志物的表达和甲状腺球体的自我更新能力,同时限制其生长能力。因此,我们认为 PATZ1 可能在增强甲状腺癌细胞的干细胞潜能方面发挥作用,但同时也会损害非干细胞的增殖。